


PHARMACEUTICAL 2022

## Aclaris Therapeutics Inc. Rank 242 of 475











The relative strengths and weaknesses of Aclaris Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aclaris Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Aclaris Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 53% points.

The company's Economic Capital Ratio, given in the ranking table, is -100%, being 177% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	205,032
Cost of Goods Sold	4,713
Intangible Assets	7,048
Liabilities, Current	22,931
Liabilities, Non-Current	2,172
Other Assets	37,796
Other Compr. Net Income	-130
Other Expenses	24,339
Other Liabilities	28,767
Other Net Income	-1,142
Property and Equipment	1,335
Research and Development	43,813
Revenues	6,761
Selling, General and Administrative Expense	23,619

Output Variable	Value in 1000 USD
Assets	251,211
Liabilities	53,870
Expenses	96,484
Stockholders Equity	197,341
Net Income	-90,865
Comprehensive Net Income	-90,930
Economic Capital Ratio	-100%

